{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T08:14:20Z","timestamp":1788164060531,"version":"build-2803163510"},"reference-count":67,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"funder":[{"DOI":"10.13039\/100000061","name":"Fogarty International Center","doi-asserted-by":"crossref","award":["D71TW013085"],"award-info":[{"award-number":["D71TW013085"]}],"id":[{"id":"10.13039\/100000061","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Clinical Pharmacology"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/17512433.2026.2723009","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T15:09:11Z","timestamp":1787756951000},"page":"761-772","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":0,"title":["Progress toward longer-acting antiretroviral regimens for adult HIV treatment"],"prefix":"10.1080","volume":"19","author":[{"given":"Logan","family":"Flaxman","sequence":"first","affiliation":[{"name":"University of South Alabama","place":["Mobile, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Onyema","family":"Ogbuagu","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit C.","family":"Achhra","sequence":"additional","affiliation":[{"name":"Yale School of Medicine","place":["New Haven, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,27]]},"reference":[{"key":"e_1_3_5_3_1","unstructured":"World Health Organization. HIV data and statistics. 2025 [cited 2026 Apr 4]. Available from: https:\/\/www.who.int\/teams\/global-hiv-hepatitis-and-stis-programmes\/hiv\/strategic-information\/hiv-data-and-statistics"},{"key":"e_1_3_5_4_1","unstructured":"Center for Disease Control and Prevention. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data\u2014United States and 6 territories and freely associated States. 2023 [cited 2025 Nov 30]. Available from: https:\/\/www.cdc.gov\/hiv-data\/nhss\/national-hiv-prevention-and-care-objectives-2025.html"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32666-0"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_5_7_1","volume-title":"Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended release injectable suspension) [Prescribing information]","author":"Viiv Healthcare","year":"2025","unstructured":"Viiv Healthcare. Cabenuva (cabotegravir extended-release injectable suspension; rilpivirine extended release injectable suspension) [Prescribing information]. Durham, NC: GSK; 2025."},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab439"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(20)30340-4"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(21)00185-5"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508228"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-021-01005-1"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.70068"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31917-7"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000003025"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad020"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(23)00136-4"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003584"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(24)00289-5"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-04041-7"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.059"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac631"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70113"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0788"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.24543"},{"key":"e_1_3_5_27_1","volume-title":"Week-24 outcomes of long-acting injectable ART in people with HIV and suboptimal viral suppression","author":"Chen N-Y","year":"2026","unstructured":"Chen N-Y, Chen C-P, Lin Y-C, et al. Week-24 outcomes of long-acting injectable ART in people with HIV and suboptimal viral suppression. Denver (CO): CROI; 2026."},{"key":"e_1_3_5_28_1","unstructured":"ViiV Healthcare. A phase 3b open-label randomized standard-of-care controlled study evaluating the efficacy safety and tolerability of injectable cabotegravir (CAB) long-acting + rilpivirine (RPV) long-acting in viremic participants living with HIV-1 (CROWN). Clinicaltrials.gov Identifier: NCT06694805; 2025 [updated 2026 March 9; cited 2026 Mar 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06694805"},{"key":"e_1_3_5_29_1","unstructured":"Gilead Sciences. Resistance summary 2026. [cited 2026 Apr 7]. Available from: https:\/\/www.biktarvyhcp.com\/efficacy-resistance\/resistance-summary"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002883"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2023.100793"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf385"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70050"},{"key":"e_1_3_5_34_1","unstructured":"Panel on antiretroviral guideline for adults and adolescents. Guildlines for the use of antiretroviral agents in adults and adolescents with HIV. Department of Health and Human Services; 2025 [updated 2025 September 25; cited 2026 Feb 28]. Available from: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-arv"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae016"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae475"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciag023"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa367"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3008.240019"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac492.106"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.13439"},{"key":"e_1_3_5_42_1","unstructured":"International AIDS Society. ViiV Healthcare announces positive new data for apretude use during pregnancy at AIDS 2024 [updated 2024 Jul 23;cited 2026 Apr 17]. Available from: https:\/\/www.natap.org\/2024\/IAS\/IAS_62.htm"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-025-00751-2"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae125"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajhp\/zxad223"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(25)00128-6"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2115542"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(22)00291-0"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/17425255.2024.2415295"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-018-0907-5"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00110-19"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_3_5_53_1","unstructured":"Theratechnologies Inc. TROGARZO\u00ae (ibalizumab-uiyk) injection for intravenous use 2023. Updated December. 2023 [cited 2026 Apr 17]. Available from: https:\/\/www.trogarzo.com\/assets\/pdf\/TROGARZO%20Prescribing%20Information.pdf"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf651"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaf597"},{"key":"e_1_3_5_56_1","unstructured":"Institut de M\u00e9decine et d\u2019Epid\u00e9miologie Appliqu\u00e9e - Fondation Internationale L\u00e9on M\u2019Ba. Cabotegravir\/Lenacapavir Dual Long-Acting Therapy (CALENDULA Cohort). Clinicaltrial.Gov identifier. 2026 [cited 2026 Mar 29]p. NCT07402044. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07402044"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanmic.2025.101283"},{"key":"e_1_3_5_59_1","volume-title":"The 20th European AIDS Conference","author":"Ogbuagu O","year":"2025","unstructured":"Ogbuagu O, McMahon J, Gaur A, et al. Efficacy and safety of a twice-yearly regimen of Lenacapavir, teropavimab, and Zinlirvimab: phase 2\u00a0week 52 results. In: The 20th European AIDS Conference; Paris, France; 2025 Oct 18."},{"key":"e_1_3_5_60_1","unstructured":"Viiv Healthcare. A study to investigate the virologic efficacy and safety of VH3810109 + cabotegravir compared to standard of care (SOC) in male and female adults living with human immunodeficiency virus (HIV) (EMBRACE). 2026 Apr 6. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05996471"},{"key":"e_1_3_5_61_1","volume-title":"2026 Conference on Retroviruses and Opportunistic Infections","author":"Rolle C","year":"2026","unstructured":"Rolle C. Maintenance of HIV suppression at 12 months with VH3810109 (N6LS) Q4M + CAB LA QM: the EMBRACE study. In: 2026 Conference on Retroviruses and Opportunistic Infections; Denver, CO; 2026 Feb 25."},{"key":"e_1_3_5_62_1","unstructured":"Gilead Sciences. Study to compare an oral weekly islatravir\/Lenacapavir regimen with standard of care in virologically suppressed people with HIV-1 (ISLEND-2). Clinicaltrials.gov Identifier: NCT06630299; 2025 [updated 2025 November 14; cited 2026 Apr 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06630299"},{"key":"e_1_3_5_63_1","unstructured":"Merck Sharp & Dohme LLC. A study of islatravir (ISL) and ulonivirine (ULO) Once weekly (QW) in virologically suppressed adults with human immunodeficiency virus type 1 (HIV-1) (MK-8591B-060). Clinicaltrials.gov Identifier: NCT06891066; 2025 [updated 2025 October 16; cited 2026 Apr 8]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06891066"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2607973"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(26)01442-X"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.12403"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0245955"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.7326\/ANNALS-25-01939"},{"key":"e_1_3_5_69_1","volume-title":"International AIDS Conference","author":"Luetkemeyer A","year":"2026","unstructured":"Luetkemeyer A, Bloch M, Scribner A, et al. Randomized, active-controlled, phase 2b study evaluating efficacy and safety of switch to islatravir (ISL) 2 mg with ulonivirine (ULO) 200 mg Once weekly in virologically suppressed adults living with HIV-1. In: International AIDS Conference; Brazil. Rio de Janeiro; 2026."}],"container-title":["Expert Review of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2026.2723009","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/17512433.2026.2723009","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/17512433.2026.2723009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T07:19:35Z","timestamp":1788160775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/17512433.2026.2723009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":67,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/17512433.2026.2723009"],"URL":"https:\/\/doi.org\/10.1080\/17512433.2026.2723009","relation":{},"ISSN":["1751-2433","1751-2441"],"issn-type":[{"value":"1751-2433","type":"print"},{"value":"1751-2441","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ierj20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-04-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-27","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}